Aethlon Medical Inc (AEMD): R&D Expense
$1.91M
Year ended 2026-03-31
-11.4%
3-year compound annual growth
-1.6%
5-year compound annual growth
+9.4%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $1.91M | -13.6% | 2026-06-10, From 2025-04-01 |
| 2025-03-31 | $2.21M | -12.2% | 2026-06-10, From 2024-04-01 |
| 2024-03-31 | $2.52M | -8.2% | 2025-06-26, From 2023-04-01 |
| 2023-03-31 | $2.75M | +17.3% | 2024-06-27, From 2022-04-01 |
| 2022-03-31 | $2.34M | +13.0% | 2023-06-28, From 2021-04-01 |
| 2021-03-31 | $2.07M | +123.5% | 2022-06-28, From 2020-04-01 |
| 2020-03-31 | $927.0K | +3.5% | 2021-06-24, From 2019-04-01 |
| 2019-03-31 | $896.0K | +52.9% | 2020-06-25, From 2018-04-01 |
| 2018-03-31 | $586.0K | -12.9% | 2019-07-01, From 2017-04-01 |
| 2017-03-31 | $673.0K | -13.9% | 2018-06-08, From 2016-04-01 |
| 2016-03-31 | $782.0K | -23.9% | 2017-06-28, From 2015-04-01 |
| 2015-03-31 | $1.03M | -31.9% | 2016-06-29, From 2014-04-01 |
| 2014-03-31 | $1.51M | +4.8% | 2015-07-13, From 2013-04-01 |
| 2013-03-31 | $1.44M | n/a | 2014-07-15, From 2012-04-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Aethlon Medical Inc (AEMD) | 2026-03-31 | $1.91M | -13.6% |
| GeoVax Labs, Inc. (GOVX) | 2025-12-31 | $18.12M | -23.6% |
| Greenwich LifeSciences, Inc. (GLSI) | 2025-12-31 | $17.22M | +11.2% |
| Vyome Holdings, Inc (HIND) | 2025-12-31 | $588.3K | +106.1% |
| Kairos Pharma, Ltd. (KAPA) | 2025-12-31 | $2.13M | +415.7% |
| Azora Therapeutics, Inc. (AZR) | 2025-12-31 | $2.62M | -18.9% |
| OS Therapies Inc (OSTX) | 2025-12-31 | $16.36M | +476.3% |
| Ernexa Therapeutics Inc. (ERNA) | 2025-12-31 | $4.16M | -9.7% |
| Serina Therapeutics, Inc. (SER) | 2025-12-31 | $13.15M | +75.9% |
Compare AEMD, GOVX, GLSI, HIND side by side · Screen every company in Pharmaceutical Preparations ↗